Business Context and Reporting Period
Company: Gilead Sciences, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: Gilead is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapeutics for life-threatening diseases, primarily HIV/AIDS, hepatitis B, and fungal infections. The company operates globally with headquarters in Foster City, California.
Key Financial Metrics
| Metric | 2008 | 2007 | Change |
|---|---|---|---|
| Total Revenues | $5,335.8 million | $4,230.0 million | +26% |
| Product Sales | $5,084.8 million | $3,733.1 million | +36% |
| Royalty Revenues | $218.2 million | $468.2 million | -53% |
| Net Income | $2,011.2 million | $1,615.3 million | +25% |
| Diluted EPS | $2.10 | $1.68 | +25% |
| Operating Cash Flow | $2,204.7 million | $1,765.4 million | +25% |
| Cash & Marketable Securities | $3,239.6 million | $2,722.4 million | +19% |
| Convertible Senior Notes | $1,300.0 million | $1,300.0 million | — |
| Product Gross Margin | 78% | 79% | -1% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26% driven by a 36% surge in product sales. Antiviral products (Truvada, Atripla, Viread, Hepsera, Emtriva) accounted for 92% of product sales, growing 36% year-over-year.
- Product Mix Shift: Atripla sales grew 74% to $1.57 billion, while Truvada sales grew 33% to $2.11 billion. The increasing proportion of Atripla sales (which includes a zero-margin component from partner Bristol-Myers Squibb) contributed to a slight decline in overall product gross margin.
- Royalty Decline: Royalty revenues dropped 53% to $218.2 million, primarily due to decreased Tamiflu sales by partner Roche related to pandemic planning initiatives.
- Expense Increases: Operating expenses rose 18% to $2.66 billion. Research and Development (R&D) expenses increased 22% to $721.8 million due to expanded clinical studies. Selling, General, and Administrative (SG&A) expenses increased 13% to $797.3 million.
- Foreign Currency Impact: A weaker U.S. dollar provided a favorable impact of approximately $148.2 million on revenues and $92.6 million on pre-tax income compared to 2007.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Management Commentary
Management anticipates continued high productivity and financial performance in 2009. Key objectives include expanding commercial markets, leveraging new international subsidiaries, and progressing R&D timelines. The company expects product gross margins to be lower in 2009 due to higher expected Atripla sales.
Risks and Contingencies
- Patent Litigation: Teva Pharmaceuticals filed an Abbreviated New Drug Application (ANDA) for a generic version of Truvada, alleging invalidity of two emtricitabine patents. Gilead filed a lawsuit in December 2008. A loss could shorten patent protection to 2017.
- Regulatory Delays: The FDA issued a complete response letter in September 2008 regarding the New Drug Application (NDA) for aztreonam for inhalation solution (cystic fibrosis), requesting an additional Phase 3 clinical study. Gilead filed for dispute resolution, but the FDA reiterated the need for further study in February 2009.
- European Credit Risk: Accounts receivable in Greece, Italy, Portugal, and Spain totaled $543.8 million, with $191.0 million more than 120 days past due due to government funding delays.
- Generic Competition: Risks include potential compulsory licenses in developing countries and generic entry for products like Flolan (patent expired) and HIV products.
Unusual Items
- Stock Repurchases: Gilead repurchased $1.97 billion of common stock in 2008 under a $3.0 billion program authorized in 2007, including two accelerated share repurchase transactions totaling $1.25 billion.
- Acquisition: Acquired Navitas Assets, LLC's cicletanine business for $10.9 million, expensed as purchased in-process R&D.
Investor Verification Checklist
- Patent Status: Verify the outcome of the litigation against Teva regarding Truvada patents and the status of the Brazilian patent application for tenofovir disoproxil fumarate.
- Regulatory Approvals: Monitor the status of the aztreonam for inhalation solution NDA and the requirement for additional clinical trials.
- European Receivables: Assess the collectibility of the $191 million in receivables over 120 days past due in Southern Europe.
- Product Mix Impact: Analyze the long-term margin impact of the growing sales mix of Atripla versus standalone Truvada.
- Accounting Changes: Review the impact of the upcoming adoption of FSP APB 14-1 on convertible debt accounting, which is expected to increase interest expense significantly in future periods.